208 related articles for article (PubMed ID: 28486102)
1. Tumor Microenvironment: No Effector T Cells without Dendritic Cells.
Pfirschke C; Siwicki M; Liao HW; Pittet MJ
Cancer Cell; 2017 May; 31(5):614-615. PubMed ID: 28486102
[TBL] [Abstract][Full Text] [Related]
2. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.
Hope C; Emmerich PB; Papadas A; Pagenkopf A; Matkowskyj KA; Van De Hey DR; Payne SN; Clipson L; Callander NS; Hematti P; Miyamoto S; Johnson MG; Deming DA; Asimakopoulos F
J Immunol; 2017 Sep; 199(5):1933-1941. PubMed ID: 28754680
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
4. Immune response regulation in the tumor microenvironment by hypoxia.
Labiano S; Palazon A; Melero I
Semin Oncol; 2015 Jun; 42(3):378-86. PubMed ID: 25965356
[TBL] [Abstract][Full Text] [Related]
5. Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy.
Tsang YW; Huang CC; Yang KL; Chi MS; Chiang HC; Wang YS; Andocs G; Szasz A; Li WT; Chi KH
BMC Cancer; 2015 Oct; 15():708. PubMed ID: 26472466
[TBL] [Abstract][Full Text] [Related]
6. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
Nagarsheth N; Wicha MS; Zou W
Nat Rev Immunol; 2017 Sep; 17(9):559-572. PubMed ID: 28555670
[TBL] [Abstract][Full Text] [Related]
7. Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.
Van Acker HH; Beretta O; Anguille S; De Caluwé L; Papagna A; Van den Bergh JM; Willemen Y; Goossens H; Berneman ZN; Van Tendeloo VF; Smits EL; Foti M; Lion E
Oncotarget; 2017 Feb; 8(8):13652-13665. PubMed ID: 28099143
[TBL] [Abstract][Full Text] [Related]
8. Role of Local Radiation Therapy in Cancer Immunotherapy.
Demaria S; Golden EB; Formenti SC
JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.
Broz ML; Binnewies M; Boldajipour B; Nelson AE; Pollack JL; Erle DJ; Barczak A; Rosenblum MD; Daud A; Barber DL; Amigorena S; Van't Veer LJ; Sperling AI; Wolf DM; Krummel MF
Cancer Cell; 2014 Nov; 26(5):638-52. PubMed ID: 25446897
[TBL] [Abstract][Full Text] [Related]
10. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
Son CH; Bae JH; Lee HR; Shin DY; Yang K; Park YS
J Immunother; 2015 Apr; 38(3):107-15. PubMed ID: 25751500
[TBL] [Abstract][Full Text] [Related]
11. Leukocyte trafficking: Can we bring the fight to the tumor?
Pachynski R; Nazha J; Kohrt H
Discov Med; 2016 Mar; 21(115):205-12. PubMed ID: 27115171
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T cells in cancer; can they be controlled?
Adeegbe DO; Nishikawa H
Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
[No Abstract] [Full Text] [Related]
13. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
[TBL] [Abstract][Full Text] [Related]
14. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
Spranger S; Sivan A; Corrales L; Gajewski TF
Adv Immunol; 2016; 130():75-93. PubMed ID: 26923000
[TBL] [Abstract][Full Text] [Related]
15. The tumor microenvironment: Thousand obstacles for effector T cells.
Massa C; Seliger B
Cell Immunol; 2019 Sep; 343():103730. PubMed ID: 29249298
[TBL] [Abstract][Full Text] [Related]
16. Biological properties of dendritic cells: implications to their use in the treatment of cancer.
van Schooten WC; Strang G; Palathumpat V
Mol Med Today; 1997 Jun; 3(6):254-60. PubMed ID: 9211416
[TBL] [Abstract][Full Text] [Related]
17. Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.
Harjunpää H; Llort Asens M; Guenther C; Fagerholm SC
Front Immunol; 2019; 10():1078. PubMed ID: 31231358
[TBL] [Abstract][Full Text] [Related]
18. IL-36 Signaling in the Tumor Microenvironment.
Chelvanambi M; Weinstein AM; Storkus WJ
Adv Exp Med Biol; 2020; 1240():95-110. PubMed ID: 32060891
[TBL] [Abstract][Full Text] [Related]
19. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
Ramachandran M; Dimberg A; Essand M
Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
[TBL] [Abstract][Full Text] [Related]
20. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.
Zhong H; Han B; Tourkova IL; Lokshin A; Rosenbloom A; Shurin MR; Shurin GV
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5455-62. PubMed ID: 17875775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
